Community/Retail

The most pronounced association was observed when individuals consumed 2 to 3 cups of caffeinated coffee per day.

Host Craig Beavers explores why US blood pressure control still lags despite proven treatments.

The Medications Optimizing Maternal Safety (MOMS) program offers vital support to pregnant patients through community pharmacies.

Ann Marie Navar, MD, PhD, explains how enlicitide’s sustained LDL-C lowering, favorable tolerability, and structured dosing may improve adherence and expand oral add-on options for patients not at goal on statins.

Pharmacists are critical in supporting GLP-1 therapy success through proactive expectation setting.

Sarah Nelson, PharmD, explains how pharmacists can simplify cardiovascular treatment regimens through personalized education, shared decision-making, and cross-sector collaboration to improve adherence and close care gaps in heart disease prevention.

Bangladesh reports fatal Nipah case linked to raw date palm sap; experts say spread stays limited as vaccines and rapid tests advance.

Although historically conceptualized as a childhood condition, it is now well established that ADHD frequently continues across the life span, with symptoms evolving rather than resolving.

The HHS secretary overstated preliminary research showing the benefits of a keto diet in patients with schizophrenia who remain adherent to medications.

The VESALIUS-CV trial demonstrates that adding evolocumab to maximally tolerated statin therapy significantly reduces major cardiovascular events in both high-risk primary and secondary prevention patients.

Pharmacists drive American Heart Month action by improving adherence, prevention, and equity.

Incremental, plant-based dietary changes can improve glycemic control, weight, and lipid outcomes while complementing cardiometabolic pharmacotherapy in routine pharmacy practice.

Embedded pharmacy experts in neurology strengthen multiple sclerosis care through education, therapy selection, lab monitoring, and collaborative practice agreements that close gaps.

The platform offers uninsured patients discounted drug prices, though it is important to note that the platform does not sell drugs, and only a small number are currently available.

The scientific statement underscores obesity as a complex, socially driven condition and positions pharmacists as key partners in reducing stigma, improving access to care, and supporting equitable weight management.

Sodium-glucose co-transporter-2 (SGLT2) inhibitors in patients with type 2 diabetes (T2D) were found to reduce the risk of chronic kidney disease (CKD) and key associated factors, like eGFR and albuminuria.

Pharmacists play a vital role in countering GLP-1 misinformation.

Pharmacist-owners occupy a unique position in health care. Unlike shareholder-driven corporate structures, pharmacist-led enterprises are uniquely positioned to balance financial health with professional obligation.

Full results detailing the safety and efficacy of enlicitide decanoate, an oral PCSK9 inhibitor, were published in The New England Journal of Medicine.

In addition to increased prevalence, the age of diagnosis has also decreased.

India has confirmed 2 Nipah infections in West Bengal as surveillance tracks 196 contacts with no spread, with the World Health Organization outlining symptoms, transmission, and response measures.

During American Heart Month, Sarah Nelson, PharmD, highlights how pharmacists can leverage frequent patient interactions, risk assessment tools, and medication optimization strategies to reduce cardiovascular risk.

Legislation targeting the practices of pharmacy benefit managers (PBMs) was passed by Congress and signed by the president, with the goal of greater transparency and increased pharmacy access.

Pharmacists enhance multiple sclerosis care through collaborative practice agreements, improving patient outcomes and bridging gaps in treatment and education.

MFN drug pricing ties Medicare payments to the lowest prices abroad, promising lower costs but sparking legal, access, and innovation concerns.

Joseph Saseen, PharmD, explains how persistent cholesterol myths undermine care and why emerging oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors could expand access to intensive LDL-C lowering.

COVID-19 significantly impacts diagnosis rates for depression, asthma, and osteoporosis, revealing health care inequities and the need for improved monitoring.

Craig Beavers is joined by the investigators of the POLY-HF trial to reinforce the critical role of pharmacist counseling and education in treating patients with heart failure.